12 completed, 5 active not recruiting, 5 terminated, 1 not yet recruiting. 15 Phase 1, 11 Phase 2, 3 Early Phase 1, 2 Phase 4, 1 Phase 3.
Follow Matrix-M: new trials by email Literature Review of Matrix-M trials Research Report on Matrix-M
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Safety, Immunogenicity and Efficacy Study of PvRII/Matrix-M in Healthy Thai Adults Living in Thailand ( MIST3 ) Malaria Vaccine, HBV vaccine - Plasmodium Vivax Infection, Malaria Vaccine | Phase 2 | Not yet recruiting | University of Oxford | 36 | 2027-01-01 | 2026-03-24 |
| Study of a Recombinant Spike COVID-19 Vaccine With Matrix-M in Older Adults and People at Increased Risk of Severe COVID-19 Omicron Subvariant-Based SARS-CoV-2 Recombinant Spike Vaccine Adjuvanted With Matrix-M - COVID-19 | Phase 4 | Recruiting | Sanofi | 660 | 2026-10-01 | 2026-10-15 |
| A Study to Assess the Experimental Malaria Vaccines R78C and RH5.1 With Matrix-M in Combination With R21/Matrix-M R21, RH5.1, R78C - Malaria,Falciparum | Phase 2 | Active not recruiting | University of Oxford | 360 | 2025-12-15 | 2026-10-21 |
| Efficacy and Safety of NVX-CoV2705 NVX-CoV2705, Placebo - COVID-19, Sars-CoV-2 Infection | Phase 4 | Terminated | Novavax | 6500 | 2025-11-20 | 2026-10-23 |
| Safety and Immunogenicity of NVX-CoV2705 NVX-CoV2705 - COVID-19, SARS-CoV-2 Infection | Phase 3 | Completed | Sanofi | 676 | 2025-10-09 | 2026-06-05 |
| A Study to Assess the Experimental Malaria Vaccines R78C and RH5.1 Combined With R21/Matrix-M (a "Multi-stage" Malaria Vaccine) R21, RH5.1, R78C - Malaria,Falciparum | Phase 1 | Active not recruiting | University of Oxford | 56 | 2025-09-15 | 2026-10-21 |
| Pfs230D1 + R21 in Matrix-M1 in African School Children and Adults 10µg of R21 with 50µg Matrix-M1, 6µg of Pfs230D1-CRM197 + 10µg of R21 with 50µg Matrix-M1 single vial coformulation, RABIVAX-S - Prevention of Malaria Transmission and Clinical Malaria | Phase 2 | Active not recruiting | Serum Institute of India Pvt. Ltd. | 1200 | 2025-08-22 | 2026-07-08 |
| Dose-Escalating Study of Pfs230D1 in Combination With R21 in Matrix-M in African Adults R21, Pfs230D1-CRM197, Pfs230D1-EPA - Prevention of Malaria Transmission and Clinical Malaria | Phase 1 | Completed | Serum Institute of India Pvt. Ltd. | 240 | 2024-08-30 | 2026-02-10 |
| Trial Evaluating the Immunogenicity and Safety of an Adjuvanted Epstein-Barr Virus (EBV) Glycoprotein 350 Vaccine in EBV-seronegative Persons Matrix-M1 Adjuvant, EBV gp350-Ferritin Vaccine, Placebo Comparator - Epstein-Barr Virus Infection, Infectious Mononucleosis | Phase 1 / Phase 2 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 25 | 2023-09-22 | 2026-04-22 |
| A Study to Assess the Safety and Effectiveness of Two Experimental Malaria Vaccines RH5.1 and/or RH5.2-VLP with Matrix-M - Malaria, Malaria,Falciparum | Phase 1 / Phase 2 | Completed | University of Oxford | 41 | 2023-08-18 | 2026-07-20 |
| A Study to Assess the Experimental Malaria Vaccines RH5.2-VLP and R21 Matrix-M with RH5.2 VLP and/or R21 - Malaria, Plasmodium Falciparum | Phase 1 | Completed | University of Oxford | 107 | 2023-07-10 | 2026-05-12 |
| A Study to Compare Two Dosing Regimens for a New Malaria Vaccine Matrix M with RH5.1 - Malaria, Malaria,Falciparum | Phase 1 | Active not recruiting | University of Oxford | 24 | 2023-06-06 | 2024-10-04 |
| A Study to Test Experimental Blood Stage Malaria Vaccine in Burkina Faso. Rabies vaccine, RH5.1 10μg adjuvated with 50μg Matrix-M, RH5.2 5μg adjuvated with 50μg Matrix-M - Malaria,Falciparum | Phase 1 / Phase 2 | Completed | University of Oxford | 390 | 2023-04-03 | 2026-10-21 |
| A Phase Ia Clinical Trial to Assess the Safety and Immunogenicity of the Blood-stage Malaria Candidate Vaccines RH5.1 in Matrix-M and R78C in Matrix-M in Healthy UK Adults Matrix M with R78C and/or RH5.1 - Malaria, Falciparum | Early Phase 1 | Active not recruiting | University of Oxford | 36 | 2023-01-13 | 2025-04-01 |
| A Study of the Plasmodium Falciparum Malaria Vaccine Candidate Pfs48/45 in Matrix-M Adjuvant in the UK Pfs48/45 in Matrix-M - Malaria, Plasmodium Falciparum | Early Phase 1 | Terminated | University of Oxford | 17 | 2022-11-02 | 2026-08-07 |
| Safety and Immunogenicity of Pvs25-IMX313/Matrix-M1 Vaccine Pvs25-IMX313/Matrix-M1 - Malaria, Vivax | Early Phase 1 | Terminated | University of Oxford | 25 | 2022-02-09 | 2026-01-15 |
| Evaluation of the Safety and Immunogenicity of Influenza and COVID-19 Combination Vaccine ICC Vaccine, qNIV Nanoparticle Vaccine2 in-clinic mixed with Matrix-M1 Adjuvant, SARS-CoV-2 rS Nanoparticle Vaccine in-clinic mixed with Matrix-M1 Adjuvant - SARS-CoV Infection, Covid19 | Phase 1 / Phase 2 | Completed | Novavax | 637 | 2021-09-08 | 2025-04-10 |
| Safety, Immunogenicity and ex Vivo Efficacy of Pfs25-IMX313/Matrix-M in Healthy Volunteers in Bagamoyo, Tanzania. Pfs25-IMX313 (10ug)/Matrix-M (50ug), Pfs25-IMX313 (50ug)/Matrix-M (50ug), Pfs25-IMX313 (50ug)/Matrix-M (50ug) & Pfs25-IMX313 (10ug)/Matrix-M (50ug) - Malaria,Falciparum | Phase 1 | Terminated | University of Oxford | 34 | 2021-05-25 | 2025-01-27 |
| Safety, Immunogenicity and Efficacy of the Blood-stage Plasmodium Vivax Malaria Vaccine Candidate PvDBPII in Matrix M1 PvDBPII/Matrix-M1 - Malaria, Vivax | Phase 1 / Phase 2 | Completed | University of Oxford | 24 | 2020-01-24 | 2024-11-25 |
| VAC077: Safety and Immunogenicity of the Pfs25-IMX313/Matrix-M Vaccine Pfs25-IMX313/Matrix-M1 - Malaria,Falciparum | Phase 1 | Terminated | University of Oxford | 1 | 2019-09-27 | 2020-09-29 |
Showing 20 of 25. Sign in to see all of them.
Malaria, Falciparum (11) · Malaria (5) · COVID-19 (4) · Infections (2) · Malaria, Vivax (2) · Parasitic Diseases (2) · Vector Borne Diseases (2) · Coronavirus Infections (1) · Epstein-Barr Virus Infections (1) · Herpes Simplex (1) · Infectious Mononucleosis (1) · Influenza, Human (1) · Protozoan Infections (1) · Severe Acute Respiratory Syndrome (1)
University of Oxford (16) · Novavax (3) · Sanofi (2) · Serum Institute of India Pvt. Ltd. (2) · Isconova AB (1) · National Institute of Allergy and Infectious Diseases (NIAID) (1)
United Kingdom (9) · Burkina Faso (4) · United States (4) · Australia (2) · Mali (2) · Hungary (1) · Tanzania (1) · Thailand (1) · The Gambia (1)
Angela M Minassian, DPhil FRCP (3) · Angela Minassian (2) · Adrian V Hill, DPhil FRCP (1) · Angela M Minassian, Dr (1) · Angela Minassian, Dr (1) · Angela Minassian, PhD (1) · Halidou Tinto (1) · Jessica R Durkee-Shock, M.D. (1) · Nicholas Day, MD (1) · Umberto D'Alessandro (1)
PMID 30774635, PMID 33964223, PMID 35664997, PMID 36087586, PMID 39672183, PMID 39805301, PMID 39805302, PMID 40245769, PMID 41176969